Epidermal Growth Factor adjuvant therapy for psoriasis
Phase 2
- Conditions
- Psoriasis.Psoriasis
- Registration Number
- IRCT20141007019432N8
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 21
Inclusion Criteria
Informed consent
Mild to moderate psoriasis (all types) with active plaques on both body sides accessible for self product application
Age 18-60 years
Exclusion Criteria
Systemic psoriasis treatment 3 months prior and during the study
Local psoriasis treatment on the investigational sites in the last 30 days or during the study
Known hypersensitivity or allergy to the EGF containing product and/or to Vaseline/10% salicylic acid
History of malignant disease Other clinically relevant concomitant disease state Participation in another investigational drug study in the last 30 days
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method